세계의 결합조직질환 치료 시장 보고서(2025년)

Connective tissue disease treatment involves managing a group of autoimmune or inflammatory disorders that impact connective tissues like joints, skin, muscles, and internal organs. The goal is to reduce inflammation, regulate immune system activity, alleviate symptoms such as pain and fatigue, and prevent disease progression and organ damage.

The primary drug classes for treating connective tissue diseases include anti-inflammatory drugs, immunosuppressants, biologics and targeted therapies, disease-modifying anti-rheumatic drugs (DMARDs), and others. Anti-inflammatory drugs help decrease inflammation, pain, and swelling by inhibiting the body's inflammatory response and are widely used in managing these diseases. These medications are prescribed for various conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, dermatomyositis, mixed connective tissue disease (MCTD), polymyositis, Sjogren's syndrome, vasculitis, and antiphospholipid syndrome (APS). Administration routes include oral, injectable, and topical forms. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, serving end users in hospitals, clinics, and homecare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The connective tissue disease treatment market research report is one of a series of new reports from The Business Research Company that provides connective tissue disease treatment market statistics, including the connective tissue disease treatment industry global market size, regional shares, competitors with the connective tissue disease treatment market share, detailed connective tissue disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the connective tissue disease treatment industry. These connective tissue disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The connective tissue disease treatment market size has grown strongly in recent years. It will grow from $23.08 billion in 2024 to $24.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the rising prevalence of autoimmune disorders, increased awareness of early diagnosis, improvements in healthcare infrastructure in developing regions, greater adoption of biologic therapies, and expanding insurance coverage for managing chronic diseases.

The connective tissue disease treatment market size is expected to see strong growth in the next few years. It will grow to $31.11 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth expected in the forecast period can be attributed to an expanding geriatric population, increased research and development investments by pharmaceutical companies, rising demand for personalized medicine, a growing pipeline of targeted therapies, and a focus on patient-centered care models. Key trends during this period include advancements in monoclonal antibody therapies, greater integration of telemedicine for disease monitoring, a shift toward biologics and biosimilars, development of multi-targeted drug regimens, and enhanced collaboration between academic and clinical research institutions.

The rising incidence of autoimmune diseases is expected to drive the growth of the connective tissue disease treatment market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks healthy tissues and organs. The increasing incidence is mainly caused by a combination of genetic susceptibility, which makes some individuals more vulnerable to immune system malfunctions, and environmental factors such as infections, diet, stress, and exposure to toxins that can trigger or worsen these conditions. Treatments for connective tissue diseases help manage autoimmune disorders by targeting the underlying immune dysfunction that leads to inflammation and tissue damage. This approach helps alleviate symptoms, slow disease progression, and improve the quality of life for patients with conditions like lupus, rheumatoid arthritis, and scleroderma. For example, in November 2024, Versorgungsatlas.de, a Germany-based healthcare data platform, reported that in 2022, 6,304,340 out of 73,241,305 insured individuals were diagnosed with at least one autoimmune disease, reflecting a raw prevalence rate of 8.61%. Therefore, the rising incidence of autoimmune diseases is fueling the growth of the connective tissue disease treatment market.

Key companies in the connective tissue disease treatment market are focusing on clinical trials to develop innovative therapies such as allogeneic CAR-NK cell therapy, aiming to improve treatment effectiveness and address unmet needs in autoimmune diseases. Allogeneic CAR-NK cell therapy involves using natural killer (NK) cells from healthy donors that are genetically engineered with chimeric antigen receptors (CAR) to specifically target and destroy disease-causing cells. This therapy boosts the immune system's ability to eliminate harmful B-cells involved in autoimmune conditions and offers a potentially safer and more accessible alternative to conventional cell therapies. For instance, in July 2024, Nkarta Inc., a US-based clinical-stage biotech firm, initiated the Ntrust-1 clinical trial to assess NKX019, an investigational allogeneic CAR-NK cell therapy for lupus nephritis. The company also received FDA approval to start a separate trial (Ntrust-2) targeting systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis, aiming to improve safety, accessibility, and efficacy in autoimmune disease treatment by using genetically engineered NK cells that selectively target CD19-expressing B-cells.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition was intended to expand Amgen's footprint in the rare and autoimmune disease market by incorporating Horizon Therapeutics' portfolio of innovative and rapidly growing biologic therapies, including Tepezza, Krystexxa, and Uplizna. The deal strengthens Amgen's pipeline, diversifies its revenue streams, and enhances its leadership position in specialty therapeutics. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company specializing in treatments for Sjogren's syndrome and rheumatoid arthritis.

Major players in the connective tissue disease treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) PLC, Eli Lilly and Company, Amgen Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Hikma Pharmaceuticals PLC, Innovent Biologics Inc., RemeGen Co. Ltd, Kymera Therapeutics, Adicet Bio, Equillium Inc., and Stem Cell Care India.

North America was the largest region in the connective tissue disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in connective tissue disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the connective tissue disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The connective tissue disease treatment market includes revenues earned by entities by providing services such as medication administration, physical rehabilitation, patient education, genetic counselling, long-term disease monitoring, and laboratory testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The connective tissue disease treatment market also includes sales of monoclonal antibodies, biologic agents, and corticosteroids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Connective Tissue Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on connective tissue disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for connective tissue disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The connective tissue disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Anti-Inammatory Drugs; Immunosuppressants; Biologics And Targeted Therapy; Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Other Drug Classes
• 2) By Disease Type: Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA); Scleroderma; Dermatomyositis; Mixed Connective Tissue Disease (MCTD); Polymyositis; Sjogren's Syndrome; Vasculitis; Antiphospholipid Syndrome (APS)
• 3) By Route Of Administration: Oral; Injectable; Topical
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Clinics; Homecare Settings
• Subsegments:
• 1) By Anti-Inflammatory Drugs: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Systemic Corticosteroids
• 2) By Immunosuppressants: Calcineurin Inhibitors; Mammalian Target Of Rapamycin (mTOR) Inhibitors; Antimetabolites; Alkylating Agents
• 3) By Biologics And Targeted Therapy: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; T-Cell Co-Stimulation Modulators; Janus Kinase (JAK) Inhibitors
• 4) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs); Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• 5) By Other Drug Classes: Analgesics; Antimalarial Drugs; Antibiotics; Monoclonal Antibodies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Sanofi S.A.; Bristol Myers Squibb Company; AstraZeneca PLC; Novartis AG; GlaxoSmithKline (GSK) PLC; Eli Lilly and Company; Amgen Inc.; Biogen Inc.; Vertex Pharmaceuticals; UCB S.A.; Hikma Pharmaceuticals PLC; Innovent Biologics Inc.; RemeGen Co. Ltd; Kymera Therapeutics; Adicet Bio; Equillium Inc.; Stem Cell Care India.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Connective Tissue Disease Treatment Market Characteristics

3. Connective Tissue Disease Treatment Market Trends And Strategies

4. Connective Tissue Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Connective Tissue Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Connective Tissue Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Connective Tissue Disease Treatment Market Growth Rate Analysis
• 5.4. Global Connective Tissue Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Connective Tissue Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Connective Tissue Disease Treatment Total Addressable Market (TAM)

6. Connective Tissue Disease Treatment Market Segmentation

• 6.1. Global Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Inammatory Drugs
• Immunosuppressants
• Biologics And Targeted Therapy
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Other Drug Classes
• 6.2. Global Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Lupus Erythematosus (SLE)
• Rheumatoid Arthritis (RA)
• Scleroderma
• Dermatomyositis
• Mixed Connective Tissue Disease (MCTD)
• Polymyositis
• Sjogren's Syndrome
• Vasculitis
• Antiphospholipid Syndrome (APS)
• 6.3. Global Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.4. Global Connective Tissue Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Connective Tissue Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• 6.6. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Systemic Corticosteroids
• 6.7. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcineurin Inhibitors
• Mammalian Target Of Rapamycin (mTOR) Inhibitors
• Antimetabolites
• Alkylating Agents
• 6.8. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Biologics And Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin-6 (IL-6) Inhibitors
• B-Cell Inhibitors
• T-Cell Co-Stimulation Modulators
• Janus Kinase (JAK) Inhibitors
• 6.9. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
• 6.10. Global Connective Tissue Disease Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antimalarial Drugs
• Antibiotics
• Monoclonal Antibodies

7. Connective Tissue Disease Treatment Market Regional And Country Analysis

• 7.1. Global Connective Tissue Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Connective Tissue Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Connective Tissue Disease Treatment Market

• 8.1. Asia-Pacific Connective Tissue Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Connective Tissue Disease Treatment Market

• 9.1. China Connective Tissue Disease Treatment Market Overview
• 9.2. China Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Connective Tissue Disease Treatment Market

• 10.1. India Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Connective Tissue Disease Treatment Market

• 11.1. Japan Connective Tissue Disease Treatment Market Overview
• 11.2. Japan Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Connective Tissue Disease Treatment Market

• 12.1. Australia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Connective Tissue Disease Treatment Market

• 13.1. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Connective Tissue Disease Treatment Market

• 14.1. South Korea Connective Tissue Disease Treatment Market Overview
• 14.2. South Korea Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Connective Tissue Disease Treatment Market

• 15.1. Western Europe Connective Tissue Disease Treatment Market Overview
• 15.2. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Connective Tissue Disease Treatment Market

• 16.1. UK Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Connective Tissue Disease Treatment Market

• 17.1. Germany Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Connective Tissue Disease Treatment Market

• 18.1. France Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Connective Tissue Disease Treatment Market

• 19.1. Italy Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Connective Tissue Disease Treatment Market

• 20.1. Spain Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Connective Tissue Disease Treatment Market

• 21.1. Eastern Europe Connective Tissue Disease Treatment Market Overview
• 21.2. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Connective Tissue Disease Treatment Market

• 22.1. Russia Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Connective Tissue Disease Treatment Market

• 23.1. North America Connective Tissue Disease Treatment Market Overview
• 23.2. North America Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Connective Tissue Disease Treatment Market

• 24.1. USA Connective Tissue Disease Treatment Market Overview
• 24.2. USA Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Connective Tissue Disease Treatment Market

• 25.1. Canada Connective Tissue Disease Treatment Market Overview
• 25.2. Canada Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Connective Tissue Disease Treatment Market

• 26.1. South America Connective Tissue Disease Treatment Market Overview
• 26.2. South America Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Connective Tissue Disease Treatment Market

• 27.1. Brazil Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Connective Tissue Disease Treatment Market

• 28.1. Middle East Connective Tissue Disease Treatment Market Overview
• 28.2. Middle East Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Connective Tissue Disease Treatment Market

• 29.1. Africa Connective Tissue Disease Treatment Market Overview
• 29.2. Africa Connective Tissue Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Connective Tissue Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Connective Tissue Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Connective Tissue Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Connective Tissue Disease Treatment Market Competitive Landscape
• 30.2. Connective Tissue Disease Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Connective Tissue Disease Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline (GSK) PLC
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Biogen Inc.
• 31.7. Vertex Pharmaceuticals
• 31.8. UCB S.A.
• 31.9. Hikma Pharmaceuticals PLC
• 31.10. Innovent Biologics Inc.
• 31.11. RemeGen Co. Ltd
• 31.12. Kymera Therapeutics
• 31.13. Adicet Bio
• 31.14. Equillium Inc.
• 31.15. Stem Cell Care India

32. Global Connective Tissue Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Connective Tissue Disease Treatment Market

34. Recent Developments In The Connective Tissue Disease Treatment Market

35. Connective Tissue Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Connective Tissue Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Connective Tissue Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Connective Tissue Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer